Background Disease-specific studies have reported impaired humoral responses after
SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated …

Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …

Background Studies have suggested incremental short-term adverse events (AE) after
repeated vaccination. In this report, we assessed occurrence and risk factors for short-term …

Objectives To compare the cumulative incidence and disease severity of reported SARS-
CoV-2 omicron breakthrough infections between patients with immune-mediated …

For patients with immune-mediated inflammatory diseases (IMIDs), concerns exist about
increased disease activity after vaccination. We aimed to assess changes in disease activity …

Abstract SARS-CoV-2-specific CD8+ T cells recognize conserved viral peptides and in the
absence of cross-reactive antibodies form an important line of protection against emerging …

Background Patients with immune-mediated inflammatory diseases (IMIDs) on
immunosuppressants (ISPs) may have impaired long-term humoral immune responses and …

Background The noninflammatory immunoglobulin G4 (IgG4) is linked to tolerance and is
unique to humans. Although poorly understood, prolonged antigenic stimulation and IL‐4 …

Background Repeated mRNA vaccination against SARS-CoV-2 has been shown to induce
class switching to IgG4, a non-inflammatory human antibody subclass linked to tolerance …

Patients with immune-mediated inflammatory diseases (IMIDs) may have impaired initial
humoral responses after SARS-CoV-2 vaccination depending on the type of …